



Medicare Advantage and Dual Medicare-Medicaid Plans Preauthorization and Notification List

Effective date: Jan. 1, 2024

Revision date: Jan. 8, 2025

| Medicare Advantage and Dual Medicare-Medicaid Plan Medication Preauthorization List | | |
|---|--|--------------|
| Access the fax forms to request preauthorization or provide notification. | | |
| Brand | Generic | Codes |
| Abecma intravenous suspension ^{††} | idecabtagene vicleucel ^{††} | Q2055 |
| Abraxane ^{‡,**,†} | nab-paclitaxel ^{‡,**,†} | J9264 |
| Actemra IV ^{**} | tocilizumab ^{**} | J3262 |
| Adakveo [‡] | crizanlizumab-tmca [‡] | J0791 |
| Adcetris | brentuximab vedotin | J9042 |
| Adstiladrin | nadofaragene firadenovec-vncg | J9029 |
| Aduhelm | aducanumab-avwa | J0172 |
| Adzynma | ADAMTS13, recombinant-krhn | J7171 |
| Akynzeo IV | fosnetupitant and palonosetron | J1454 |
| Aldurazyme | laronidase | J1931 |
| Alimta [‡] | pemetrexed [‡] | J9305 |
| Aliqopa | copanlisib | J9057 |
| Aloxi | palonosetron HCL | J2469 |
| Alyglo ^{‡, †, ‡, **,†} | immune globulin intravenous, human-stwk ^{‡, †, ‡, **,†} | C9399, J1599 |
| Alymsys ^{**} | bevacizumab-maly ^{**} | Q5126 |
| Amondys-45 | casimersen | J1426 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|--|---|----------------------------|
| Amtagvi †, ‡, *, †† | lifileucel †, ‡, *, †† | C9399, J3490, J9999 |
| Amvuttra | vutrisiran | J0225 |
| Anktiva †, ‡, * | nogapendekin alfa inbakicept-pmln †, ‡, * | C9169, J3490, J3590, J9999 |
| Aphexda | motixafortide | J2277 |
| Aralast NP †, ** | alpha 1-proteinase inhibitor †, ** | J0256 |
| Aranesp ** | darbepoetin alfa ** | J0881 |
| Arcalyst | riloncept | J2793 |
| Asceniv ** | immune globulin ** | J1554 |
| Asparlas | calaspargase pegol-mknl | J9118 |
| Aucatzyl †, ‡, *, †† | obecabtagene autoleucel †, ‡, *, †† | C9399, J3490, J9999 |
| Avastin (<i>authorization required only for oncology/chemo use</i>) ** | bevacizumab (oncology only) ** | C9257, J9035 |
| Aveed | testosterone undecanoate | J3145 |
| Avsola †, ** | infliximab-axxq †, ** | Q5121 |
| Axtle †, ‡, * | pemetrexed †, ‡, * | C9399, J3490, J9999 |
| Azedra | iobenguane I 131 | A9590, C9407, C9408 |
| Bavencio | avelumab | J9023 |
| Beleodaq | belinostat | J9032 |
| Belrapzo † | bendamustine hydrochloride † | J9036 |
| bendamustine † | bendamustine hydrochloride † | J9036 |
| bendamustine (Apotex) | bendamustine hydrochloride | J9058 |
| bendamustine (Baxter) | bendamustine hydrochloride | J9059 |
| Bendeka | bendamustine hydrochloride | J9034 |
| Benlysta | belimumab | C9399, J0490, J3590 |
| Beovu ** | brocuzumab-dbll ** | J0179 |
| Berinert ** | c1 esterase inhibitor ** | J0597 |
| Besponsa | Inotuzumab ozogamicin | J9229 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---|--|----------------------------|
| Bivigam** | immune globulin** | J1556 |
| Bizengri ^{†, ‡, *} | zenocutuzumab-zbco ^{†, ‡, *} | C9399, J3490, J3590, J9999 |
| Blenrep [‡] | belantamab mafodotin-blmf [‡] | J9037 |
| Blincyto | blinatumomab | J9039 |
| Blood-clotting factors (see list on pages 17–19) | | |
| bortezomib [‡] | bortezomib [‡] | J9041 |
| bortezomib (Dr. Reddy's) | bortezomib | J9046 |
| bortezomib (Fresenius Kabi) | bortezomib | J9048 |
| bortezomib (Hospira) | bortezomib | J9049 |
| bortezomib (Maia) | bortezomib | J9051 |
| Boruzu ^{†, ‡, *} | bortezomib ^{†, ‡, *} | C9399, J3490, J9999 |
| Botox | onabotulinumtoxinA | J0585 |
| Brineura | cerliponase alfa | J0567 |
| Briumvi ^{†, **} | ublituximab-xiiy ^{†, **} | J2329 |
| Breyanzi ^{††} | lisocabtagene maraleucel ^{††} | Q2054 |
| Byooviz ^{**} | ranibizumab-nuna intravitreal solution ^{**} | Q5124 |
| cabazitaxel (Sandoz) | cabazitaxel | J9064 |
| Carvykti ^{††} | ciltacabtagene autoleucel ^{††} | Q2056 |
| Casgevly ^{*, †, ‡, ††} | exagamglogene autotemcel ^{*, †, ‡, ††} | C9399, J3490 |
| Cerezyme | imiglucerase | J1786 |
| Cimerli ^{**} | ranibizumab-eqrn ^{**} | Q5128 |
| Cimzia | certolizumab pegol | J0717 |
| Cinqair | reslizumab | J2786 |
| Cinryze ^{**} | c1 esterase inhibitor (human) ^{**} | J0598 |
| Cinvanti | aprepitant | C9145, J0185 |
| Cosela | trilaciclib | J1448 |
| Cortrophin Gel | adrenocorticotrophic hormone (ACTH) | J0802 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|------------------------------|--|---------------------|
| Columvi ^{††,*} | glofitamab-gxbm ^{††,*} | J9286 |
| Cosentyx IV ^{**} | secukinumab ^{**} | J3247 |
| Crysvita | burosumab-twza | J0584 |
| Cutaquig ^{**} | immune globulin ^{**} | J1551 |
| Cuvitru ^{**} | immune globulin | J1555 |
| Cyklokapron [‡] | tranexamic acid [‡] | J3490 |
| Cyramza | ramucirumab | J9308 |
| Darzalex | daratumumab | J9145 |
| Darzalex Faspro [‡] | daratumumab and hyaluronidase-fihj [‡] | J9144 |
| Danyelza | naxitamab-gqgk | J9348 |
| Daxxify ^{**} | daxibotulinumtoxinA-lanm ^{**} | J0589 |
| Defitelio [‡] | defibrotide sodium [‡] | C9399, J3490 |
| Docivyx ^{†,†,*} | docetaxel ^{†,†,*} | C9399, J3490, J9999 |
| Doxil | doxorubicin HCL liposome injection | Q2050 |
| Duopa | carbidopa/levodopa | J7340 |
| Dupixent [‡] | dupilumab [‡] | C9399, J3590 |
| Durysta [‡] | bimatoprost implant [‡] | J7351 |
| Dysport | abobotulinumtoxin A | J0586 |
| Elahere ^{†,*} | mirvetuximab soravtansine-gynx ^{†,*} | J9063 |
| Elaprase | idursulfase | J1743 |
| Elelyso | taliglucerase alfa | J3060 |
| Elevidys ^{†,*} | delandistrogene moxeparvovec-rokl ^{†,*} | J1413 |
| Elfabrio IV ^{†,*} | pegunigalsidase alfa-iwxj ^{†,*} | J2508 |
| Elitek | rasburicase | J2783 |
| Elrexio | elranatamab-bcmm | J1323 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|-----------------------------|--|---------------------|
| Elzonris | tagraxofusp-erzs | J9269 |
| Empaveli [†] | pegcetacoplan [†] | C9399, J3490 |
| Empliciti | elotuzumab | J9176 |
| Enhertu | fam-trastuzumab deruxtecan-nxki | J9358 |
| Enjaymo | sutimlimab-jome | J1302 |
| Enspryng [†] | satralizumab-mwge [‡] | C9399, J3490, J3590 |
| Entyvio IV ^{**} | vedolizumab ^{**} | J3380 |
| Epkinly ^{†,*} | epcoritamab-bysp ^{†,*} | J9321 |
| Epogen ^{†,**} | epoetin alfa ^{†,**} | J0885, Q4081 |
| Erbitux | cetuximab | J9055 |
| Erwinase [‡] | crisantaspase [‡] | J9019 |
| Erwinaze [‡] | asparaginase erwinia chrysanthemi [‡] | J9019 |
| Eskata [‡] | hydrogen peroxide [‡] | C9399, J3490 |
| Euflexxa ^{**} | sodium hyaluronate ^{**} | J7323 |
| Evenity ^{**} | romosozumab-aqqg ^{**} | J3111 |
| Evkeeza | evinacumab-dgnb | J1305 |
| Exondys 51 | eteplirsen | J1428 |
| Eylea | aflibercept | J0178 |
| Eylea HD | aflibercept | J0177 |
| Fabrazyme | agalsidase beta | J0180 |
| Fasenra | benralizumab | J0517 |
| Faslodex | fulvestrant | J9395 |
| Feraheme ^{**} | ferumoxytol ^{**} | Q0138 |
| Firazyr ^{†,**} | icatibant ^{†,**} | J1744 |
| Flebogamma [‡] | immune globulin [‡] | J1572 |
| Flebogamma DIF [‡] | immune globulin [‡] | J1572 |
| Flolan [‡] | epoprostenol (injection) [‡] | J1325, J3490, S0155 |
| Foloty [‡] | pralatrexate [‡] | J9307 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|--|---|--------------|
| Fulphila | pegfilgrastim-jmdb | Q5108 |
| fulvestrant (Teva) | fulvestrant | J9393 |
| fulvestrant (Fresenius Kabi) | fulvestrant | J9394 |
| Fusilev † | levoleucovorin calcium † | J0641 |
| Fyarro | sirolimus protein-bound particles for injectable suspension | J9331 |
| Fylnetra †,*,** | pegfilgrastim-pbbk †,*,** | Q5130 |
| GamaSTAN † | immune globulin † | J1460, J1560 |
| GamaSTAN S/D † | immune globulin † | J1460, J1560 |
| Gamifant | emapalumab-lzsg | J9210 |
| Gammagard | immune globulin | J1569 |
| Gammagard S/D † | immune globulin † | J1566 |
| Gammaked † | immune globulin † | J1561 |
| Gammaplex ** | immune globulin ** | J1557 |
| Gamunex-C † | immune globulin † | J1561 |
| Gazyva | obinutuzumab | J9301 |
| Gel-One ** | sodium hyaluronate ** | J7326 |
| Gelsyn-3 ** | sodium hyaluronate ** | J7328 |
| Genvisc 850 ** | sodium hyaluronate ** | J7320 |
| Givlaari | givosiran | J0223 |
| Glassia ** | alpha 1-proteinase inhibitor ** | J0257 |
| Granix ** | tbo-filgrastim ** | J1447 |
| Growth hormones: Genotropin, Humatrope, Norditropin FlexPro, Nutropin AQ NuSpin, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive † | somatropin † | J2941 |
| H.P. Acthar Gel | corticotropin | J0801 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---|---|-------------------------------|
| Haegarda | c1 esterase inhibitor (subcutaneous) | J0599 |
| Herceptin** | trastuzumab** | J9355 |
| Herceptin Hylecta ^{†, **} | trastuzumab and hyaluronidase- oysk ^{†, **} | J9356 |
| Hercessi IV ^{*, †, ‡, **} | trastuzumab-strf ^{*, †, ‡, **} | C9399, J3490, J3590, J9999 |
| Herzuma** | trastuzumab-pkrb** | Q5113 |
| Hizentra | immune globulin | J1559 |
| Hyalgan ^{†, **} | sodium hyaluronate ^{†, **} | J7321 |
| Hymovis** | sodium hyaluronate** | J7322 |
| Hyqvia** | immune globulin** | J1575 |
| iDose TR 75 mcg intracameral implant | travoprost intracameral implant | J7355 |
| Ilaris | canakinumab | J0638 |
| Ilumya** | tildrakizumab-asmn** | J3245 |
| Iluvien | fluocinolone acetonide | J7313 |
| Imdelltra ^{*, †, ‡} | tarlatamab-dlle ^{*, †, ‡} | C9170, J3490, J3590, J9999 |
| Imfinzi | durvalumab | J9173 |
| Imjudo ^{†, *} | tremelimumab-actl ^{†, *} | J9347 |
| Imlygic | talimogene laherparepvec | J9325 |
| Inflectra | infliximab-dyyb | Q5103 |
| Infliximab | infliximab | J1745 |
| Injectafer** | ferric carboxymaltose** | J1439 |
| Istodax | romidespin | J9319 |
| Ixempra | ixabepilone | J9207 |
| Izervay | avacincaptad pegol intravitreal solution | J2782 |
| Jelmyto [†] | mitomycin [†] | J9281 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|----------------------|---|---------------------|
| Jemperli** | dostarlimab-gxly** | J9272 |
| Jevtana | cabazitaxel | J9043 |
| Kadcyla | ado-trastuzumab emtansine | J9354 |
| Kalbitor** | ecallantide** | J1290 |
| Kanjinti | trastuzumab-anns | Q5117 |
| Kanuma | sebelipase alfa | J2840 |
| Kebilidi †,*, ‡, †† | eladocagene exuparvovec-tneq †,*, ‡, †† | C9399, J3490, J3590 |
| Keytruda | pembrolizumab | J9271 |
| Khapzory | levoleucovorin | J0642 |
| Kimmtrak | tebentafusp-tebn | J9274 |
| Kisunla *, † | donanemab-azbt *, † | J0175 |
| Korsuva † | difelikefalin † | J0879 |
| Krystexxa | pegloticase | J2507 |
| Kymriah †† | tisagenlecleucel †† | Q2042 |
| Kyprolis | carfilzomib | J9047 |
| Lamzede †, * | velmanase alfa-tycv †, * | J0217 |
| Lantidra *, ‡, †† | donislecel-jujn *, ‡, †† | C9399, J3490, J3590 |
| lanreotide *, †, ‡ | lanreotide *, †, ‡ | J1930 |
| lanreotide (Cipla) | lanreotide | J1932 |
| Lemtrada** | alemtuzumab** | J0202 |
| Lenmeldy †, *, ‡, †† | atidarsagene autotemcel †, *, ‡, †† | C9399, J3490 |
| Leqembi †, * | lecanemab-irmb †, * | J0174 |
| Leqvio | inclisiran | J1306 |
| Leukine | sargramostim | J2820 |
| Levoleucovorin † | levoleucovorin calcium † | J0641 |
| Libtayo | cemiplimab-rwlc | J9119 |
| Loqtorzi | toripalimab-tpzi | J3263 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|-----------------------------|--|---------------------|
| Lucentis** | ranibizumab** | J2778 |
| Lumizyme | alglucosidase alfa | J0221 |
| Lunsumio ^{†,*} | mosunetuzumab-axgb ^{†,*} | J9350 |
| Lutathera** | lutetium Lu 177 dotatate** | A9513 |
| Luxturna | voretigene neparvovec-rzyl | J3398 |
| Lyfgenia ^{††} | lovotibeglogene autotemcel ^{††} | J3394 |
| Macrilen [‡] | macimorelin [‡] | C9399, J8499 |
| Margenza | margetuximab-cmkb | J9353 |
| Mepsevii | vestronidase alfa-vjkb | J3397 |
| Mircera | methoxy polyethylene glycol- epoetin beta | J0887, J0888 |
| Monjuvi [‡] | tafasitamab-cxix [‡] | J9349 |
| Monoferic** | ferric derisomaltose** | J1437 |
| Mozobil [‡] | plerixafor [‡] | J2562 |
| Mvasi | bevacizumab-awwb | Q5107 |
| Mylotarg | gemtuzumab ozogamicin | J9203 |
| Myobloc | rimabotulinumtoxinB | J0587 |
| Naglazyme | galsulfase | J1458 |
| Neulasta [‡] | pegfilgrastim [‡] | J2506 |
| Neulasta Onpro [‡] | pegfilgrastim [‡] | J2506 |
| Neupogen** | filgrastim** | J1442 |
| Nexviazyme | avalglucosidase alfa-ngpt | J0219 |
| Ngenla ^{†,‡,*} | somatrogon-ghla ^{†,‡,*} | C9399, J3490, J3590 |
| Nivestym | filgrastim-aafi | Q5110 |
| Nplate | romiplostim | J2796 |
| Nucala | mepolizumab | J2182 |
| Nulibry [‡] | fosdenopterin [‡] | C9399, J3490 |
| Nulojix | belatacept | J0485 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---|---|----------------------------|
| Nuwiq | simoctocog alfa | J7209 |
| Nypozi ^{*, †, ‡, **} | filgrastim-txid ^{*, †, ‡, **} | C9173, J3490, J3590, J9999 |
| Nyvepria ^{‡, **} | pegfilgrastim-apgf ^{‡, **} | Q5122 |
| Ocrevus | ocrelizumab | J2350 |
| Ocrevus Zunovo ^{†, ‡, *} | ocrelizumab and hyaluronidase-acsq ^{†, ‡, *} | C9399, J3490, J3590 |
| Octagam | immune globulin | J1568 |
| Ogivri ^{**} | trastuzumab-dkst ^{**} | Q5114 |
| Omisirge ^{*, †, ‡} | omidubicel-only ^{*, †, ‡} | C9399, J3490, J3590 |
| Omvoh IV ^{‡, ‡, **} | mirikizumab-mrkz ^{‡, ‡, **} | J2267 |
| Oncaspar | pegaspargase | J9266 |
| Onivyde ^{**} | irinotecan liposome injection ^{**} | J9205 |
| Onpattro | patisiran | J0222 |
| Ontruzant ^{**} | trastuzumab-dttb ^{**} | Q5112 |
| Opdivo | nivolumab | J9299 |
| Opdualag intravenous vial ^{**} | nivolumab and relatlimab-rmbw injection ^{**} | J9298 |
| Orencia IV ^{**} | abatacept ^{**} | J0129 |
| Oxlumo | lumasiran | J0224 |
| Ozurdex | dexamethasone intravitreal implant | J7312 |
| paclitaxel protein-bound ^{**} | paclitaxel protein-bound ^{**} | J9258 |
| Padcev [‡] | enfortumab vedotin-ejfv [‡] | J9177 |
| Palyngiq [‡] | pegvaliase-pqz [‡] | C9399, J3490, J3590 |
| Panzyga | immune globulin | J1576 |
| Parsabiv | etelcalcetide | J0606 |
| Pavblu ^{*, †, ‡, **} | aflibercept-ayyh ^{*, †, ‡, **} | C9399, J3490, J3590 |
| Pedmark IV solution ^{†, *} | sodium thiosulfate ^{†, *} | J0208 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|--------------------------------|--|---------------------|
| pemetrexed | pemetrexed | J9305 |
| pemetrexed (Accord) | pemetrexed | J9296 |
| pemetrexed (Bluepoint) | pemetrexed | J9322 |
| pemetrexed (Hospira) | pemetrexed | J9294, J9323 |
| pemetrexed (Sandoz) | pemetrexed | J9297 |
| pemetrexed (Teva) | pemetrexed | J9314 |
| Pemfexy | pemetrexed injection | J9304 |
| Pemrydi RTU * | pemetrexed * | J9324 |
| Perjeta | pertuzumab | J9306 |
| Phesgo [†] | pertuzumab, trastuzumab, and hyaluronidase-zzxf [†] | J9316 |
| Piasky ^{‡,‡,*} | crovalimab-akkz ^{‡,‡,*} | C9399, J3490, J3590 |
| plerixafor [‡] | plerixafor [‡] | J2562 |
| Pluvicto | lutetium lu 177 vipivotide tetraxetan | A9607 |
| Polivy | polatuzumab vedotin-piiq | J9309 |
| Pombiliti | cipaglicosidase alfa-atga | J1203 |
| Portrazza | necitumumab | J9295 |
| Poteligeo | mogamulizumab-kpkc | J9204 |
| pralatrexate IV ^{‡,*} | pralatrexate ^{‡,*} | J9307 |
| Prevymis IV [‡] | letermovir [‡] | C9399, J3490 |
| Prialt | ziconotide | J2278 |
| Privigen | immune globulin | J1459 |
| Procrit [‡] | epoetin alfa [‡] | J0885, Q4081 |
| Prolastin-C ^{‡,**} | alpha 1-proteinase inhibitor ^{‡,**} | J0256 |
| Prolia | denosumab | J0897 |
| Provenge | sipuleucel-T | Q2043 |
| Qalsody ^{‡,*} | tofersen ^{‡,*} | J1304 |
| Qutenza | capsaicin/skin cleanser | J7336 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|------------------------------|---|---------------------|
| Radicava | edaravone | J1301 |
| Reblozyl** | luspatercept-aamt ^{†, **} | J0896 |
| Releuko** | filgrastim-ayow injection** | Q5125 |
| Remicade | infliximab | J1745 |
| Remodulin [‡] | treprostinil (injection) [‡] | J3285, J3490 |
| Renflexis** | infliximab-abda** | Q5104 |
| Retacrit | epoetin alfa-epbx | Q5105, Q5106 |
| Rethymic ^{*, †, ††} | allogeneic processed thymus tissue-agdc ^{*, †, ††} | C9399, J3490, J3590 |
| Retisert | fluocinolone acetonide | J7311 |
| Revatio [‡] | sildenafil citrate (injection) [‡] | J3490, J8499 |
| Riabni** | rituximab-arrx** | Q5123 |
| Rituxan** | rituximab** | J9312 |
| Rituxan Hycela** | rituximab/hyaluronidase human** | J9311 |
| Roctavian ^{*, †} | valoctocogene roxaparvovec-rvox ^{*, †} | J1412 |
| Rolvedon ^{†, *, **} | eflapegrastim-xnst ^{†, *, **} | J1449 |
| romidepsin | romidepsin | J9318 |
| Ruconest** | c1 esterase inhibitor** | J0596 |
| Ruxience ^{‡, **} | rituximab-pvvr ^{‡, **} | Q5119 |
| Rybrevant IV | amivantamab-vmjw | J9061 |
| Rylaze | asparaginase erwinia chrysanthemi (recombinant)-rywn | J9021 |
| Ryplazim | plasminogen, human-tvmh | J2998 |
| Rystiggo ^{†, *, **} | rozanolixizumab-noli ^{†, *, **} | J9333 |
| Rytelo IV ^{†, *, ‡} | imetelstat ^{†, *, ‡} | C9399, J3490 |
| Sajazir [‡] | icatibant [‡] | J1744 |
| Sandostatin LAR | octreotide | J2353 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|-------------------------------------|---|---------------------|
| Saphnelo intravenous solution | anifrolumab-fnia | J0491 |
| Sarclisa [‡] | isatuximab-irfc [‡] | J9227 |
| Scenesse [‡] | afamelanotide [‡] | J7352 |
| Signifor LAR ^{**} | pasireotide ^{**} | J2502 |
| Simponi ARIA | golimumab | J1602 |
| Sinuva | mometasone furoate | J7402 |
| Skyrizi IV | risankizumab-rzaa | J2327 |
| Skysona ^{*, ‡, ††} | elivaldogene autotemcel ^{*, ‡, ††} | C9399, J3490, J3590 |
| sodium hyaluronate ^{‡, **} | sodium hyaluronate ^{‡, **} | C9399, J3490 |
| sodium thiosulfate (Hope) | sodium thiosulfate | J0209 |
| Sogroya ^{‡, *, ‡} | somapacitan-beco ^{‡, *, ‡} | C9399, J3490, J3590 |
| Soliris | eculizumab | J1300 |
| Somatuline Depot [‡] | lanreotide [‡] | J1930 |
| Spevigo IV | spesolimab-sbzo | J1747 |
| Spinraza | nusinersen | J2326 |
| Spravato [‡] | esketamine [‡] | S0013, G2082, G2083 |
| Stelara (IV only) | ustekinumab (IV only) | J3358 |
| Stimufend ^{‡, *, **} | pegfilgrastim-fpgk ^{‡, *, **} | Q5127 |
| Strensiq [‡] | asfotase alfa [‡] | C9399, J3590 |
| Sustol | granisetron | J1627 |
| Susvimo ^{**} | ranibizumab ^{**} | J2779 |
| Syfovre | pegcetacopian | J2781 |
| Synagis | palivizumab | 90378 |
| SynoJoynt ^{**} | 1% sodium hyaluronate ^{**} | J7331 |
| Synribo | omacetaxine mepesuccinate | J9262 |
| Synvisc ^{‡, **} | hylan G-F 20 ^{‡, **} | J7325 |
| Takhzyro ^{**} | lanadelumab-flyo ^{**} | J0593 |

* New preauthorization requirement

‡ New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---|--|----------------------------|
| Takhzyro subcutaneous ^{†,*,**} | lanadelumab-flyo ^{†,*,**} | J0593 |
| Talvey | talquetamab-tgvs | J3055 |
| Tecartus ^{††} | brexucabtagene autoeucel ^{††} | Q2053 |
| Tecelra ^{*,†,‡,††} | afamitresgene autoleucel ^{*,†,‡,††} | C9399, J3490, J9999 |
| Tecentriq | atezolizumab | J9022 |
| Tecentriq Hybreza SQ ^{*,†,‡} | atezolizumab and hyaluronidase-tqjs ^{*,†,‡} | C9399, J3490, J3590, J9999 |
| Tecvayli ^{†,*} | teclistamab-cqyv ^{†,*} | J9380 |
| Tegsedi [†] | inotersen [†] | C9399, J3940 |
| Tepezza [†] | teprotumumab-trbw [†] | J3241 |
| Tevimbra ^{*,†} | tislelizumab-jsgr ^{*,†} | J9329 |
| Tezspire | tezepelumab-ekko | J2356 |
| Tezspire subcutaneous pen injector ^{†,*} | tezepelumab-ekko ^{†,*} | J2356 |
| Tivdak ^{**} | tisotumab vedotin-tftv ^{**} | J9273 |
| Thrombate III | antithrombin III (human) | J7197 |
| Tofidence IV ^{*,†,**} | tocilizumab-bavi ^{*,†,**} | Q5133 |
| Trazimera | trastuzumab-qyyp | Q5116 |
| Treanda | bendamustine hydrochloride | J9033 |
| Tremfya IV ^{*,†,‡} | guselkumab ^{*,†,‡} | J1628 |
| Triluron ^{**} | sodium hyaluronate ^{**} | J7332 |
| Triptodur | triptorelin | J3316 |
| Trisenox | arsenic trioxide | J9017 |
| TriVISC ^{**} | sodium hyaluronate ^{**} | J7329 |
| Trodelyv [†] | sacituzumab govitecan-hziy [†] | J9317 |
| Truxima ^{**} | rituximab-abbs ^{**} | Q5115 |
| Tyenne IV ^{†,**} | tocilizumab-aazg ^{†,**} | Q5135 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---------------------------------------|---|---------------------|
| Tysabri** | natalizumab** | J2323 |
| Tyvaso | treprostinil (inhaled) | J7686 |
| Tzield ^{†,*} | teplizumab-mzvw ^{†,*} | J9381 |
| Udenyca [‡] | pegfilgrastim-cbqv [‡] | Q5111 |
| Udenyca autoinjector ^{†,‡,*} | pegfilgrastim-cbqv ^{†,‡,*} | Q5111 |
| Udenyca Onbody ^{†,‡,*} | pegfilgrastim-cbqv ^{†,‡,*} | Q5111 |
| Ultomiris | ravulizumab-cwvz | J1303 |
| Unituxin | dinutuximab | J1246 |
| Uplizna [‡] | inebilizumab-cdon [‡] | J1823 |
| Uptravi [‡] | selexipag [‡] | C9399, J3490 |
| Vabysmo** | faricimab-svoa injection** | J2777 |
| Valstar | valrubicin | J9357 |
| VariZIG | varicella zoster immune globulin | 90396 |
| Vectibix | panitumumab | J9303 |
| Vegzelma ^{†,*,**} | bevacizumab-adcd ^{†,*,**} | Q5129 |
| Velcade [‡] | bortezomib [‡] | J9041 |
| Veletri [‡] | epoprostenol [‡] | J1325 |
| Ventavis | iloprost (inhaled) | Q4074, J1749 |
| Veopoz ^{†,‡,*} | pozelimab-bbfg ^{†,‡,*} | C9399, J3490, J3590 |
| Viltepro | viltolarsen | J1427 |
| Vimizim | elosulfase alfa | J1322 |
| Visco-3 ^{‡,**} | sodium hyaluronate ^{‡,**} | J7321 |
| Visudyne** | verteporfin** | J3396 |
| Vivimusta ^{†,*} | bendamustine hydrochloride ^{†,*} | J9056 |
| Vpriv** | velaglucerase alfa** | J3385 |
| Vyepti [‡] | eptinezumab-jjmr [‡] | J3032 |
| Vyjuvek ^{†,*} | beremagene geperpavec-svdt ^{†,*} | J3401 |
| Vyloy ^{*,†,‡} | zolbetuximab-clzb ^{*,†,‡} | C9399, J3490, J3590 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|------------------------------|---|----------------------------|
| Vyondys 53 | golodirsen | J1429 |
| Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc | J9334 |
| Vyvgart intravenous solution | efgartigimod alfa-fcab | J9332 |
| Vyxeos | daunorubicin/cytarabine | J9153 |
| Wainua ^{†,‡} | eplontersen injection ^{†,‡} | C9399, J3490 |
| Wezlana IV ^{†,*} | ustekinumab-auub ^{†,*} | Q5138 |
| Xembify | immune globulin | J1558 |
| Xenpozyme | olipudase alfa-rpcp | J0218 |
| Xeomin | incobotulinumtoxin A | J0588 |
| Xgeva ^{†,**} | denosumab ^{†,**} | J0897 |
| Xipere | triamcinolone acetonide | J3299 |
| Xofigo | radium Ra 223 dichloride | A9606 |
| Xolair | omalizumab | J2357 |
| Yervoy | ipilimumab | J9228 |
| Yescarta ^{††} | axicabtagene ciloleucel ^{††} | Q2041 |
| Yondelis | trabectedin | J9352 |
| Yutiq | fluocinolone acetonide intravitreal implant | J7314 |
| Zaltrap | ziv-aflibercept | J9400 |
| Zarxio | filgrastim-sndz | Q5101 |
| Zavesca ^{†,**} | miglustat ^{†,**} | J8499 |
| Zemaira [†] | alpha 1-proteinase inhibitor [†] | J0256 |
| Zepzelca [†] | lurbinectedin [†] | J9223 |
| Zevalin | ibritumomab tiuxetan | A9543 |
| Ziextenzo ^{**} | pegfilgrastim-bmez ^{**} | Q5120 |
| Ziihera ^{†,‡,*} | zanidatamab-hrii ^{†,‡,*} | C9399, J3490, J3590, J9999 |
| Zilretta ^{**} | triamcinolone acetonide ^{**} | J3304 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---------------------------|---|----------------------------|
| Zirabev | bevacizumab-bvzr | Q5118 |
| Zoladex | goserelin acetate | J9202 |
| Zolgensma [‡] | onasemnogene abeparvovec-xioi [‡] | J3399 |
| Zulresso [‡] | brexanolone [‡] | J1632 |
| Zynlonta | loncastuximab tesirine-lpyl | J9359 |
| Zynteglo ^{††} | betibeglogene autotemcel ^{††} | J3393 |
| Zynyz | retifanlimab-dlwr | J9345 |
| Blood-clotting Factors | | |
| Advate [‡] | antihemophilic factor (recombinant) [‡] | J7192 |
| Adynovate | antihemophilic factor (recombinant), PEGylated | J7207 |
| Afstyla | antihemophilic factor (recombinant) single chain | J7210 |
| Alphanate | antihemophilic factor/von Willebrand factor complex (human) | J7186 |
| AlphaNine SD [‡] | coagulation factor IX (human) [‡] | J7193 |
| Alprolix | coagulation factor IX (recombinant) | J7201 |
| Altuviio | efanesoctocog alfa | J7214 |
| BeneFix [‡] | coagulation factor IX (recombinant) [‡] | J7195 |
| Beqvez ^{*, †, ‡} | fidanacogene elaparvovec-dzkt ^{*, †, ‡} | C9172, J3490, J3590, J7199 |
| Coagadex | coagulation factor X (human) | J7175 |
| Corifact | factor XIII concentrate (human) | J7180 |
| Eloctate | antihemophilic factor (recombinant), Fc fusion protein | J7205 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|------------------------------|--|----------------------------|
| Esperoct | antihemophilic factor (recombinant), glycopegylated-exei | J7204 |
| Feiba NF | anti-inhibitor coagulant complex | J7198 |
| Hemgenix ^{†,*} | etranacogene dezaparvovec-drlb ^{†,*} | J1411 |
| Hemlibra ^{**} | emicizumab-kxwh ^{**} | J7170 |
| Hemofil M [‡] | antihemophilic factor (human) [‡] | J7190 |
| Humate-P | antihemophilic factor/von Willebrand factor complex (human) | J7187 |
| Hympavzi ^{*,†,‡,**} | marstacimab-hncq ^{*,†,‡,**} | C9399, J3490, J3590, J7199 |
| Idelvion | coagulation factor IX (recombinant) [‡] | J7202 |
| Ixinity [‡] | coagulation factor IX (recombinant) [‡] | J7213 |
| Jivi [‡] | antihemophilic factor (recombinant), PEGylated-aucl [‡] | J7208 |
| Koate-DVI [‡] | antihemophilic factor (human) [‡] | J7190 |
| Kogenate FS [‡] | antihemophilic factor (recombinant) [‡] | J7192 |
| Kovaltry | antihemophilic factor (recombinant) | J7211 |
| Monoclate-P [‡] | antihemophilic factor (human) [‡] | J7190 |
| Mononine [‡] | coagulation factor IX (human) [‡] | J7193 |
| NovoEight | turoctocog alfa | J7182 |
| NovoSeven RT | coagulation factor VIIa (recombinant) | J7189 |
| Nuwiq | simoctocog alfa | J7209 |
| Obizur | antihemophilic factor (recombinant), porcine sequence | J7188 |
| Profilnine [‡] | factor IX complex [‡] | J7194 |
| Rebinyn | coagulation factor IX (recombinant), GlycoPEGylated | J7203 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.

**Medicare Advantage and Dual Medicare-Medicaid Plan
Medication Preauthorization List**

[Access the fax forms](#) to request preauthorization or provide notification.

| Brand | Generic | Codes |
|---|---|----------------------------|
| Recombinant [†] | antihemophilic factor (recombinant) [‡] | J7192 |
| Rixubis | coagulation factor IX (recombinant) | J7200 |
| Roctavian ^{†, ‡, *} | α ₂ glycoctogene roxaparvovec-rvox | C9399, J3490, J3590, J7190 |
| SevenFact intravenous solution [†] | coagulation factor VIIa (recombinant)-jncw [‡] | J7212 |
| Tretten | coagulation factor XIII A-subunit (recombinant) | J7181 |
| Vonvendi | von Willebrand factor (recombinant) | J7179 |
| Wilate | von Willebrand factor/coagulation factor VIII complex (human) | J7183 |
| Xyntha | antihemophilic factor (recombinant) | J7185 |
| Xyntha Solofuse | antihemophilic factor (recombinant) | J7185 |

* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.

** Step therapy required through a Humana preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to 502-508-9300, by telephone at 866-421-5663 or by email to transplant@humana.com.